Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study

2012 ◽  
Vol 27 (1) ◽  
pp. 286-294 ◽  
Author(s):  
Toshihiko Shinohara ◽  
Seiji Satoh ◽  
Seiichiro Kanaya ◽  
Yoshinori Ishida ◽  
Keizo Taniguchi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cohort Study ◽  
Advanced Gastric Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
D2 Gastrectomy

scholarly journals Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Zhen Sun ◽  
Rui-Juan Zhu ◽  
Gui-Fang Yang ◽  
Yan Li
Keyword(s):  
Gastric Cancer ◽  
Cohort Study ◽  
Neoadjuvant Chemotherapy ◽  
Adverse Events ◽  
Advanced Gastric Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
R0 Resection ◽  
Ki 67 ◽  
Lymph Nodes Dissection

Background/Aim. To evaluate the clinical efficacy of FOLFOX4 (5-fluomumcil/leucovorin combined and oxaliplatin) neoadjuvant chemotherapy for advanced gastric cancer (AGC).Patients and Methods. Fifty-eight AGC patients were enrolled in this retrospective cohort study, 23 in the neoadjuvant group and 35 in the adjuvant group. R0 resection, survival, and adverse events were compared.Results. The two groups were well-matched, with no significant differences in R0 resection rate (82.6% versus 82.0%) and number of lymph nodes dissection (16 (0–49) versus 13 (3–40)) between the two groups(P>0.05). The number of lymph node metastases in the neoadjuvant group (3 (0–14)) was significantly fewer than that in the adjuvant group (6 (0–27))(P=0.04). The neoadjuvant group had significantly better median overall survival (29.0 versus 22.0 months) and 3-year survival rate (73.9% versus 40.0%) than the adjuvant group(P=0.013). The positive expression rate of Ki-67 in the neoadjuvant group (40.0%, 8/20) was lower than that in the adjuvant group (74.2%, 23/31;P=0.015).Conclusion. The FOLFOX4 neoadjuvant chemotherapy could improve survival without increasing adverse events in patients with AGC.

scholarly journals Clinical impact of small advanced gastric cancer (≤ 40 mm) in elderly patients: A retrospective cohort study

2017 ◽  
Vol 45 ◽  
pp. 131-137 ◽  
Author(s):  
Yoshitake Ueda ◽  
Hajime Fujishima ◽  
Teijiro Hirashita ◽  
Hidefumi Shiroshita ◽  
Tsuyoshi Etoh ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cohort Study ◽  
Elderly Patients ◽  
Advanced Gastric Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Clinical Impact

scholarly journals Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study

2012 ◽  
Vol 16 (3) ◽  
pp. 383-388 ◽  
Author(s):  
Shinichi Hasegawa ◽  
Chikara Kunisaki ◽  
Hidetaka Ono ◽  
Takashi Oshima ◽  
Shoichi Fujii ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cohort Study ◽  
Advanced Gastric Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort

scholarly journals A retrospective cohort study to investigate the incidence of cancer-related weight loss during chemotherapy in gastric cancer patients

2020 ◽  
Vol 29 (1) ◽  
pp. 341-348 ◽  
Author(s):  
Masaru Fukahori ◽  
Masayuki Shibata ◽  
Satoshi Hamauchi ◽  
Eiji Kasamatsu ◽  
Koji Machii
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Weight Loss ◽  
Cohort Study ◽  
Adverse Events ◽  
Advanced Gastric Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
First Line ◽  
Line Chemotherapy

Abstract Purpose This study aimed to evaluate cancer-related weight loss (WL) after the start of first-line chemotherapy as a surrogate marker for cancer cachexia in patients with advanced gastric cancer. We investigated the incidence of WL and the relationship between WL and overall survival (OS) or adverse events. Methods We conducted a retrospective cohort study in 131 patients with advanced gastric cancer who received first-line systemic chemotherapy between September 1, 2010, and August 31, 2016, at Kurume University Hospital and Shizuoka Cancer Center Hospital. WL was defined in this study as weight loss of > 5% or weight loss of > 2% with a body mass index of < 20 kg/m2 within the last 6 months after the start of chemotherapy. Results Median age and median Eastern Cooperative Oncology Group performance status of the patients participating in this study were 68 years old and 0, respectively. Incidence of WL was 53% at the first 12 weeks after starting first-line chemotherapy, and increased to 88% after 48 weeks. Overall survival rates were significantly associated with WL at 12, 24, and 48 weeks. Appetite loss and fatigue were more frequent and more severe in patients with WL. Conclusion WL was especially observed in more than half the patients within 12 weeks after starting chemotherapy. WL appeared to relate to adverse events or reduced survival. These results suggest the importance of monitoring WL or providing nutritional support at the beginning of chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document